ArticleFrontiers in veterinary science2026
Short-term effects of pimobendan in dogs with preclinical myxomatous mitral valve disease.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pimobendan has been shown to delay the onset of congestive heart failure and prolong survival in dogs affected by myxomatous mitral valve disease (MMVD). However, little information is available regarding its short-term echocardiographic effects in dogs with preclinical disease. The aim of this prospective multicenter observational study was to evaluate the effect of pimobendan on selected echocardiographic indices after 7 days of therapy in dogs with American College of Veterinary Internal Medicine stage B2 MMVD. Methods: Forty-two client-owned dogs received pimobendan orally at 0.25-0.3 mg/kg every 12 h and underwent echocardiographic examination before treatment initiation and after 7 days. Results: Significant reduction was observed in several indices of left atrial and left ventricular remodeling, including normalized left atrial diameter ( Discussion: These findings suggest that pimobendan administration is associated with early improvement in echocardiographic indices of left heart remodeling in dogs with ACVIM stage B2 MMVD and may reduce regurgitant volume shortly after treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.